Table 8. Correlation of signatures and metabolic groups in Komen subjects with reported use of metformin or anti-inflammatory drugs.
| Cluster | |||||
|---|---|---|---|---|---|
| 2 | 3 | 4 | 6 | P-value | |
| Cluster size, N | 22 | 13 | 1 | 3 | |
| T2D, N (%) | 16 (73) | 11 (85) | 0 | 1 (33) | > 0.05 |
| T2D drug, N (%) | 7 (44) | 8 (73) | -- | 0 (0) | 1 |
| T2D using metformin, N (%) | 8 (50) | 4 (36) | -- | 0 (0) | 1 |
| NSAID users, N (%) | 7 (32) | 5 (38) | 0 | 1 (33) | > 0.05 |
| HTN, N (%) | 16 (73) | 10 (77) | 0 | 1 (33) | > 0.05 |
| HTN drug, N (%) | 6 (27) | 3 (23) | 1 (100) | 3 (100) | 0.021 |
| CVD, N (%) | 3 (14) | 3 (23) | 0 | 2 (67) | > 0.05 |
| CVD and HTN drug, N (%) | 6 (27) | 2 (15) | 0 | 0 | > 0.05 |
| Lipid lowering drug, N (%) | 11 (50) | 7 (54) | 0 | 0 | > 0.05 |
| Mean BMI, kg/m2 (SD) | 33.72 (5.85) | 37.61 (8.85) | 39.45 | 28.49 (0.49) | > 0.05 |
| Mean age, y (SD) | 59.41 (7.20) | 57.92 (8.39) | 62.00 | 51.67 (5.03) | > 0.05 |
| Mean inflammation score (SD) | -6.51 (4.72) | 4.57 (6.37) | 31.40 | 17.46 (10.16) | < 0.001 |
Characteristics of Komen subjects [50] allocated to four of the six signatures discovered in the BHWS. T2D (%), percentage of subjects in each cluster with T2D; T2D drug, percentage of T2D subjects using T2D drug; T2D using metformin, percentage of subjects using metformin. P-values were calculated using χ2 tests and ANOVA.
Abbreviations: BMI, Body Mass Index; CVD, cardiovascular disease; HTN, hypertension; NSAID, non-steroidal anti-inflammatory drug; T2D, Type 2 diabetes.